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Summary We investigated the trace element status in Crohn’s disease (CD) patients receiving
enteral nutrition, and evaluated the effects of trace element-rich supplementation. Thirty-one
patients with CD were enrolled in this study. All patients were placed on an enteral nutrition
regimen with Elental® (Ajinomoto pharmaceutical. Ltd., Tokyo, Japan). Serum selenium, zinc
and copper concentrations were determined by atomic absorption spectroscopy. Serum sele-
noprotein P levels were determined by an ELISA system. Average serum levels of albumin,
selenium, zinc and copper were 4.1 ± 0.4 g/dl, 11.2 ± 2.8 µg/dl, 71.0 ± 14.8 µg/dl, and
112.0 ± 25.6 µg/dl, respectively. In 9 patients of 31 CD patients, serum albumin levels were
lower than the lower limit of the normal range. Serum selenium, zinc and copper levels were
lower than lower limits in 12 patients, 9 patients and 1 patient, respectively. Serum selenium
levels significantly correlated with both serum selenoprotein P levels and glutathione
peroxidase activity. Supplementation of selenium (100 µg/day) and zinc (10 mg/day) for 2
months significantly improved the trace element status in CD patients. In conclusion, serum
selenium and zinc levels are lower in many CD patients on long-term enteral nutrition. In
these patients, supplementation of selenium and zinc was effective in improving the trace
element status.
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Introduction
Patients with Crohn’s disease (CD) reveal various
malnutrition statuses [1–3]. In many studies, deficiencies in
trace elements, such as selenium and zinc, have been
reported as characteristic features of malnutrition in CD
patients [4–7]. Insufficient oral intake and malabsorption
have been considered to be the major causes of trace element
deficiencies [1]. Surgical resection of the small intestine
may also reduce the absorption activity of trace elements
through decreases in the mucosal absorption area. In
addition, since parenteral and enteral nutrition are widely
accepted to be effective for inducing and maintaining
remission [8–10], CD patients sometimes receive parenteral
or enteral nutrition for the management of their disease.
Most of the parenteral and enteral formulas commonly used
in Japan and the USA do not contain sufficient trace
elements [8, 10–12], and lead to inadequate supplies of trace
elements. In particular, long-term treatment with parentaral
or enteral nutrition may induce high-risk trace element
deficiencies in CD patients.
In this study, we investigated the trace element status in
CD patients, and evaluated the effects of trace element-rich
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supplementation.
Subjects and Methods
Patients
Thirty-one patients with CD (9 women and 22 men,
median age 31 years old) receiving home enteral nutrition
were enrolled in this study. All patients were managed in the
Division of Gastroenterology at the Hospital of the Shiga
University of Medical Science. The ethics committee of the
Shiga University of Medical Science approved this study. All
patients had the diagnosis of CD established by radiological,
histological, and clinical criteria.
All patients had low disease activities [Crohn’s disease
activity index (CDAI)<150 [13]], and these patients were
regarded as inactive phase. All patients were placed on
an enteral nutrition regimen with Elental® (Ajinomoto
pharmaceutical. Ltd., Tokyo, Japan). The daily caloric intake
from the enteral nutrition was 1,093 ± 239 (mean ± SD) kcal
for over 1 year. The Elental® formula contains a very small
amount of selenium and zinc.
A selenium and zinc-rich supplement (V-Accel®, Nutri
Co., Tokyo, japan) was used. The daily dosage of V-Acccel®
contained 100 µg selenium and 10 mg zinc.
Blood was sampled with the patients’ informed consent,
immediately separated to serum by centrifugation, and kept
at −80°C until use.
Analytical methods
Serum selenium and zinc concentrations were determined
by atomic absorption spectroscopy. Other laboratory data
were measured by routine methods at the Hospital of the
Shiga University of Medical Science. Serum selenoprotein P
levels were determined by a previously described ELISA
system [6]. Glutathione peroxidase (GPx) activity was
determined by a method described by Lowrence et al. [14].
Statistical analysis
Differences between groups were analyzed with the
Kruskal-Wallis test. A p value<0.05 was considered to be
statistically significant. Correlations were investigated with
Spearman rank correlation test.
Result
Serum levels of albumin, selenium, zinc and copper were
determined in 31 CD patients receiving eneteral nutrition. In
our hospital, normal ranges of serum levels of albumin,
selenium, zinc and copper ranged from 4.0 to 5.2 g/dl, from
10.6 to 17.4 µg/dl, from 64 to 111 µg/dl, and from 70 to 132 µg/
dl, respectively. As shown in Fig. 1, average levels of albumin,
selenium, zinc and copper were 4.1 ± 0.4 g/dl, 11.2 ± 2.8 µg/
dl, 71.0 ± 14.8 µg/dl, and 112.0 ± 25.6 µg/dl, respectively. In
9 of the 31 CD analyzed patients, serum albumin levels were
lower than the lower limit of the normal range. Similarly, serum
selenium, zinc and copper levels were lower than the lower
limits in 12 patients, 9 patients and 1 patient, respectively.
Selenium is incorporated into proteins via the selenium-
containing amino acids selenocysteine and selenomethionine.
A selenoprotein is a selenocystein-containing protein, and GPx
and selenoprotein P are representative serum selenoproteins.
To clarify the significance of serum selenium levels, we
assessed the relationship between serum selenium and
selenoprotein P levels and the relationship between serum
selenium levels and GPx activity. As shown in Fig. 2, a
significant correlation was found between serum selenium
and selenoprotein P levels and between serum selenium and
GPx activity, respectively. However, there are no significant
correlations between serum albumin levels and these factors
(serum selenium, selenoprotein P and GPx activity).
In 8 patients whose serum selenium levels were under the
lower limit of normal range, we evaluated the effects of
selenium- and zinc-rich supplementation. In these patients,
no significant correlation between serum trace element
levels and albumin levels was observed. Patients orally
received selenium-and zinc-rich supplement, and after 2
months changes in serum selenium and zinc levels were
determined. The daily dosage of the supplement contained
100 µg of selenium and 10 mg of zinc. As shown in Fig. 3,
administration of the selenium- and zinc-rich supplement
significantly increased serum selenium, zinc levels and GPx
activitiy. However, due to a lack of copper in the supplement,
Fig. 1.  Serum albumin, selenium, zinc and copper levels in
patients with Crohn’s disease receiving enteral nutrition
for over one year. Dark areas indicate normal ranges.
Bars indicate the mean ± SD.Trace Elements and Crohn’s Disease
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Fig. 2.  Correlations among serum selenium levels, selenoprotein P and GPx levels. (A) Correlations between selenium levels and
selenoprotein P levels. (B) Correlation between selenium levels and GPx activity. (C) Correlations between GPx activity and
selenoprotein P levels.
Fig. 3. Effects of selenium- and zinc-rich supplementation. Each data point indicates the mean ± SD (n =8 ) .  * p<0.05.T. Johtatsu et al.
J. Clin. Biochem. Nutr.
200
copper levels were not affected. Serum albumin levels did
not change after supplementation.
Discussion
Deficiencies in trace elements, such as selenium and zinc,
have been reported in various clinical studies as an indication
of malnutrition in CD patients [4, 7, 8, 15–17]. Selenium is
an essential trace element that is a component of GPx, a
scavenger of hydroperoxides [18]. A selenium deficiency
causes a decrease in GPx function, thereby resulting in
oxidative damage to many organs. In humans severe
selenium deficiencies have been linked to the development
of Keshan disease, a dilated congestive cardiomyopathy that
primarily occurs in children living in China [19]. Zinc is
present in over 80 metalloenzymes that are involved in all
the major human metabolic pathways in humans. Zinc is
necessary for cell proliferation and has an important role
in the maintenance of cellular immunity [16, 17]. An acute
zinc deficiency leads to the development of acrodermatitis,
alopecia, diarrhea and depression, and chronic zinc deficiencies
cause growth retardation, anorexia, immune disturbance and
skin lesions [16].
In this study, we observed that serum selenium and zinc
levels were lower than the lower limits of normal ranges in
38.7 and 29.0 % of CD patients receiving enteral nutrition
for a long time period, respectively. In contrast, copper
levels were normal in most of the patients. The findings
reported herein are consistent with previous reports [4, 15].
Trace element deficiencies in CD patients may result from
a variety of processes, including reduced dietary intake,
impaired mucosal absorption, increased excretion, and
hypoalbuminemia [16]. In these processes, two factors may
be important: mucosal malabsorption of trace elements and
trace element-deficient nutrition. Nishida et al. previously
demonstrated that zinc absorption is reduced even in histo-
logically normal jejunal mucosa [20]. A similar mechanism
might be applied for selenium absorption. CD patients
sometimes receive parenteral nutrition or enteral nutrition
for the management of malnutrition [8–10], and selenium
and zinc deficiencies occurs in CD patients who are
nourished alone by parentaral or enteral nutrition for a long
period of time [7, 8, 10, 11]. Trace element deficiencies are
associated with inadequate supplies of trace elements by
parentaral and enteral nutrition, since most of the parentaral
or enteral formulas do not contain sufficient trace elements
[8,  10–12]. Thus, with the use of parenteral and enteral
nutrition in CD patients, much attention should be paid to
avoid the development of trace element deficiencies. All of
our cases were inactive phase of disease, and major factor
contributed to low serum selenium and zinc levels might be
inadequate supplies of trace elements by enteral nutrition.
Selenoprotein P contains 10 selenocystein residues per
molecule, and is a plasma protein that carries more than
50% of the plasma selenium [6, 21, 22]. Selenoprotein P
is an important selenium supplier from the liver to the
peripheral tissues [22]. More importantly, selenoprotein P is
a free radical scavenger for peroxynitrite and phospholipid-
hydroperoxide [6]. Like GPx, selenoprotein P is an important
serum antioxidant factor, and protects cells from oxidative
stress. In this study, serum selenium levels were associated
with serum selenoprotein P levels and GPx activity,
suggesting that the antioxidant status might be reduced in
CD patients receiving enteral nutrition for a long period of
time. Since it has been suggested that active oxygen species
play an important role in the pathogenesis of inflammatory
bowel diseases (IBD) [6, 18], improvements in the selenium
status might be relevant to reduce disease activity.
Based on findings of lower serum trace element levels,
we orally administered selenium and zinc-rich supplement
in 8 patients. As initially expected, selenium and zinc
supplementation significantly improved selenium and zinc-
status in these patients. Although no consensus has been
reached on the dosage of trace elements to be administered,
the recommended therapeutic dose of selenium ranges from
100 µg to 400 µg/day [23,  24]. Zinc requirements range
from 2 mg to 12 mg/day [16]. Our supplementation formula
consisted of 100 µg/day of selenium and 10 mg/day of zinc,
and was sufficient for CD patients receiving enteral
nutrition. Improvements in the trace element status suggest
that trace element supplementation should be performed in
CD patients receiving long-term entral nutrition. No patients
showed symptoms of lower trace elements, and this might be
du to that clinical symptoms appear as a result of longer-term
and much severer reduction of serum trace element levels.
However, the antioxidant status in these patients might be
recovered through improvement in selenium deficiency.
In conclusion, selenium and zinc deficiencies should be
considered in CD patients receiving enteral nutrition for a
long period of time. In these patients, selenium (100 µg/day)
and zinc (10 mg/day) supplementation for 2 months was
effective in improving the trace element status.
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